Navigation Links
Immunomic Therapeutics Begins Phase I Japanese Red Cedar JRC-LAMP-Vax Vaccine Safety Study
Date:11/8/2012

LANCASTER, Pa. and ROCKVILLE, Md., Nov. 8, 2012 /PRNewswire/ -- Immunomic Therapeutics, Inc., ("ITI," Lancaster, PA) a leader in developing novel allergy immunotherapies, announced today that it has dosed the first patient in a Phase I clinical trial of its lead candidate, JRC-LAMP-vax™ vaccine, at its clinical site in Honolulu, Hawaii. Initial subjects include Japanese ex-patriates previously exposed to Japanese red cedar, or "Sugi," as it is known in Japan. JRC-LAMP-vax vaccine is a plasmid-based DNA vaccine that will be studied for its safety and immunological activity in the treatment of patients with rhino-conjunctivitis symptoms caused by allergic reaction to Japanese red cedar pollen. Enrollees in the study each received the first of a four (4) dosing vaccine regimen and were followed for 3 hours; no adverse events were observed in these patients.

ITI intends to complete enrollment in the study in November, the dosing of all patients early in 2013, and to follow up with a Phase II trial beginning in 2013. ITI's CEO, Dr. William Hearl, commented, "The successful initiation of this clinical study marks a significant milestone in the history of Immunomic Therapeutics. We are both pleased and excited that we are now a clinical - stage company. We are looking forward to completing the study and advancing the development of this important vaccine and other LAMP-vax™ vaccines."

Dr. Bruce F. Mackler, Vice President of Regulatory and Clinical Affairs, Immunomic Therapeutics, Inc., indicated that "ITI is committed to the rapid expansion of its clinical program based on the outcome of this first Japanese red cedar vaccine. We plan to move rapidly into the clinical testing of the multivalent vaccine in naturally sensitive Japanese ex-patriates as well as U.S. subjects with sensitivity to mountain cedar. This study will support our food allergy program which will treat peanut allergy in sensitive patients; that study should begin in 2013."

In Japan, it is estimated that up to 45% of the Japanese people are allergic to Japanese red cedar pollen. In North America, especially Texas, individuals suffer from a closely related allergy to mountain cedar pollen. During this Phase I study, ITI will also be monitoring the response to mountain cedar allergens in these subjects.

Key to the success of ITI's vaccines is the incorporation of LAMP Technology. Pre-clinical studies have documented that LAMP-based vaccines induce a protective antibody IgG immune response consistent with a preferential MHC-II immune system presentation induced by LAMP. Multiple studies applying LAMP Technology in human clinical trials have shown that incorporation of the LAMP element dramatically increases the CD4+ response to the target antigen. In addition to providing important safety data on LAMP, the studies confirm that LAMP vaccines activate the human immune system. LAMP-based vaccines hold potential for the development of potent vaccines for treatment of allergies, infectious disease and cancer.

About Immunomic Therapeutics Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company headquartered in Lancaster, PA with lab facilities in Rockville, MD. ITI is developing next generation vaccines based on the patented LAMP Technology. Our LAMP-vax™ vaccine platform significantly increases the effectiveness of the immune response to nucleic acid vaccines while simplifying overall vaccine design and delivery, yielding safer, more cost-effective human and animal therapies. Our LAMP constructs have been validated in human clinical trials for cancer and have been applied to a wide breadth of targets including allergy, cancer and infectious diseases. For more information about ITI and LAMP Technology please visit www.immunomix.com

CONTACT:
Dr. Bill Hearl, President / CEO
Immunomic Therapeutics, Inc.
Phone: 1-717-327-1919
Immunomix@gmail.com
Web: www.immunomix.com

 


'/>"/>
SOURCE Immunomic Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Stemline Therapeutics Lead Clinical Candidate SL-401 Induces a Complete Response in a Patient with a Drug-Refractory Plasmacytoid Dendritic Cell Neoplasm
2. Echo Therapeutics Announces Third Quarter 2012 Financial Results
3. Orexigen Therapeutics Reports Financial Results for the Third Quarter Ended September 30, 2012
4. Particle Sciences Develops Novel Ocular Formulation for Eyeon Therapeutics
5. Halozyme Therapeutics To Present At The Lazard Capital Markets 9th Annual Healthcare Conference
6. Novelos Therapeutics Closes $2 Million Private Placement
7. US Allows Two Key Patents for Silence Therapeutics
8. United Therapeutics Corporation Reports Third Quarter 2012 Financial Results
9. Cell Therapeutics, Inc. (CTI) Reduces Net Loss for Third Quarter and Nine Months Ended September 30, 2012 Compared to Same Periods in 2011
10. Novelos Therapeutics Announces Enrollment of First Patient in Solid Tumor Imaging Trial with I-124-CLR1404 (LIGHT) Cancer-targeted PET Imaging Agent at UW Carbone Cancer Center
11. United Therapeutics Announces Collaboration With Ascendis Pharma To Develop Self-Injectable Treprostinil For Pulmonary Arterial Hypertension
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2016)... NEW YORK , May 20, 2016 ... yet many veteran investors believe that the industry is ... this space, and today ActiveWallSt.com featured the following four ... Athersys Inc. (NASDAQ: ATHX ), Aralez Pharmaceuticals ... Inc. (NASDAQ: INFI ). Sign up for ...
(Date:5/19/2016)... Calif. , May 19, 2016  According ... thirds of the world lacks basic diagnostic imaging. ... in the United States , ... to such technology. In fact, the WHO reports ... risk of avoidable or treatable death, simply due ...
(Date:5/19/2016)... 19, 2016 A new report ... Market -Opportunities and Forecasts, 2015 -2022, projects that the ... 2022, registering a CAGR of 5.1% from 2015 to ... be the highest revenue-generating segment throughout the forecast period. ... one-third of the market share in 2015, and is ...
Breaking Medicine Technology:
(Date:5/24/2016)... ... May 24, 2016 , ... Bio-Logic Aqua® ... for forty years and a trainer for Ageless Grace ( http://www.agelessgrace.com ) to ... Show on May 16, 2016. , Formerly a Northwestern University Literature Professor, Kinst ...
(Date:5/24/2016)... Forest Lake, Minnesota (PRWEB) , ... May 24, ... ... his 13th mission trip to the Dominican Republic on September 21, 2016. Dr. ... Biology from Northwestern, serves with ChiroMission, a not-for-profit organization promoting health and wellness ...
(Date:5/24/2016)... ... May 24, 2016 , ... Clarion ... and safety labels , has been featured in the National Electrical Manufacturers ... eiXtra e-newsletter provides electroindustry professionals with manufacturer, regulatory, and standardization news. The publication ...
(Date:5/24/2016)... ... 2016 , ... Researchers from Catholic Health Initiatives (CHI) presented ... complications from percutaneous coronary intervention (PCI). The data, presented at the annual meeting ... a 40% reduction in risk-adjusted bleeding event rates over a two-year period across ...
(Date:5/24/2016)... ... May 24, 2016 , ... Applications such as ... are widely used for cell and protein analysis. Keeping updated on practical considerations ... efficiency in these areas. , LabRoots introduces a new complementary interactive virtual ...
Breaking Medicine News(10 mins):